TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02989142

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: INTER-ACT
Description: Pre-conception coaching sessions: We encourage less motivated women to participate to the trial by collaborating with Kind \& Gezin from the very beginning, as most timepoints of the counselling sessions coincide with the time points of the Kind\&Gezin vaccine scheme (postpartum week 6, week 8, week 12, 6 months). We will organize the coaching in a mother and baby friendly community-based setting or in the hospitals, as preferred by the mothers.~Pregnancy coaching sessions: take place in hospital, at the time of the three planned ultrasound scans.~By consequence, the applied methodology can be applied as such at the moment of global utilisation in Flanders.
Study: NCT02511509

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bifrontal electroconvulsive therapy
Description: The centre of each electrode will be placed 4-5 cm above the outer canthus of the eye along a vertical line perpendicular to a line connecting the pupils.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bitemporal electroconvulsive therapy
Description: The centre of the stimulus electrodes will be applied 2-3 cm above the midpoint of the line connecting the outer canthus of the eye and the external auditory meatus on each side of the individual's head.
Study: NCT01478620

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canephron® N
Description: 3x 2 coated tablets/day for 7 days p.o.
Study: NCT00249821

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saizen®
Description: Saizen® \[somatropin (recombinant deoxyribonucleic acid \[rDNA\] origin) for injection\], a r-hGH, is indicated for the treatment of children with growth failure due to inadequate secretion of endogenous growth hormone.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saizen®
Description: Saizen® \[somatropin (rDNA origin) for injection\], a r-hGH, is indicated for the treatment of children with growth failure due to inadequate secretion of endogenous growth hormone.
Study: NCT00640978

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RAD001
Description: 30 mg orally weekly for 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: 150 mg by mouth daily for 28 Days
Study: NCT02117583

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone
Description: One capsule of 40 mg PF-00345439 Formulation K, taken whole, single dose, under fasting conditions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone
Description: One capsule of 40 mg PF-00345439 Formulation K, taken whole, single dose, under fed conditions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone
Description: One capsule of 40 mg PF-00345439 Formulation K, Chewed, single dose, under fasting conditions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone
Description: One capsule of 40 mg PF-00345439 Formulation K, Chewed, single dose, under fed conditions
Study: NCT04664842

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Diaphragmatic Stretch Technique
Description: Diaphragmatic stretch technique is an intervention intended to indirectly stretch the diaphragmatic muscle fibers. This will help to decease tension generated by trigger points, normalizing muscle ﬁber length, and improve muscle contraction.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diaphragmatic Stretch Technique
Description: Diaphragmatic stretch technique is an intervention intended to indirectly stretch the diaphragmatic muscle fibers. This will help to decease tension generated by trigger points, normalizing muscle ﬁber length, and improve muscle contraction.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diaphragmatic Stretch Technique
Description: Diaphragmatic stretch technique is an intervention intended to indirectly stretch the diaphragmatic muscle fibers. This will help to decease tension generated by trigger points, normalizing muscle ﬁber length, and improve muscle contraction.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Breathing Exercise Training
Description: During diaphragmatic or abdominal breathing training, inhalation will caused diaphragm contract downwards, inflating the lungs. This filling of the lungs pushes the abdominal organs down leading to expansion of the abdomen. Subjects are required to do few repetitions during the intervention.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Breathing Exercise Training
Description: During diaphragmatic or abdominal breathing training, inhalation will caused diaphragm contract downwards, inflating the lungs. This filling of the lungs pushes the abdominal organs down leading to expansion of the abdomen. Subjects are required to do few repetitions during the intervention.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Breathing Exercise Training
Description: During diaphragmatic or abdominal breathing training, inhalation will caused diaphragm contract downwards, inflating the lungs. This filling of the lungs pushes the abdominal organs down leading to expansion of the abdomen. Subjects are required to do few repetitions during the intervention.
Study: NCT01989065

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Lifestyle counseling
Description: see arm description

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle counseling
Description: see arm description

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Text Messaging
Description: See Arm Description
Study: NCT04399109

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TCC-COVID mHealth solution
Description: Patients place their index finger in the pulse oximeter to measure their oxygen saturation and pulse rate twice a day, which will take approximately 5 minutes each time. Patients then enter the results into the TCC-COVID app twice daily, and complete a symptom questionnaire via the TCC-COVID app once daily, which will take approximately 5 minutes. The symptom questionnaire was designed specifically for this study. The measurements and information are directly connected to a clinician interface (KIOLA database) which provides the data of all patients in aggregate and an easy to use responsive format with customisable alerts. The alerts identify if the oxygen saturation levels are low or the pulse rate is out of range. The alerts also identify if a measurement has not been completed in a timely manner and the central monitoring service will contact the patient to check on their safety or if they are experiencing any technical issues. The overall duration of participation will be 14 days.
Study: NCT03979807

Intervention type: DRUG
Intervention: Olodaterol/Tiotropium Bromide
Description: (Stiolto®) delivered via Respimat inhaler

Intervention type: DRUG
Intervention: Umeclidinium/ Vilanterol
Description: (Anoro®) delivered via Ellipta Inhaler
Study: NCT02478866

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BPI-9016M
Description: Seven dose cohorts will be evaluated, including 100mg, 200mg, 300mg, 450mg，600mg, 800mg, 1000mg. BPI-9016M will be administered orally to patients once daily for each dose cohort.
Study: NCT03359330

Intervention type: OTHER
Intervention: Degradable Conduit Small Gap Tublization
Description: Degradable Conduit Small Gap Tublization Repairing Peripheral Nerve Injury
Study: NCT04061616

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PASIPD-Fr
Description: Fill-out the PASIPD-Fr self questionaire twice (2 completions at a 2-week interval)
Study: NCT04303520

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: anti-CD19/CD22 CAR-T cells
Description: Retroviral vector-transduced autologous T cells to express anti-CD19 and anti-CD22 CARs
Study: NCT00367965

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eszopiclone
Description: eszopiclone 3 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo tablet
Study: NCT04303520

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 30mg/m2/d

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 500mg/m2/d
Study: NCT00652626

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: azacitidine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: azacitidine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: azacitidine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: azacitidine
Study: NCT02092558

Intervention type: DRUG
Intervention: Second-generation cephalosporin, nitrofurantoin, 1% aminoglycoside solution

Intervention type: DRUG
Intervention: cephalosporin with chemotherapeutics
Description: Second-generation cephalosporin was prescribed for 10 days, and then treatment crossover with chemotherapeutics in therapeutic dose (change in every week) during 3 months
Study: NCT00622180

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NBUVB
Description: NBUVB hand foot box

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Monochromacitc Excimer light
Description: Treatment with Monochromacitc Excimer light
Study: NCT04243070

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: 3-channel Holter ECG recording
Description: 3-channel Holter ECG recording for patients undergoing an EPS

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: 12-channel Holter ECG recording
Description: 12-channel Holter ECG recording for patients undergoing a routine follow-up
Study: NCT03899168

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Social Tag Popularity
Description: The relative size of treatment tags in a tag cloud was either larger for antidepressant treatments or psychotherapy treatments.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Confidence in Prior Attitudes
Description: Participants thought back of situations in which they were either confident or doubtful about their own knowledge. This should elicit a mindset where participants are more or less confident about their own prior attitudes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Source Credibility
Description: The source credibility of the community that allegedly collected and labelled the blog posts was either high or low in terms of expertise. Either experts (high credibility) or first semester students (low credibility) did allegedly collect blog posts. This was indicated by banners on top of the navigation platform in the internet browser.
Study: NCT00652626

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: azacitidine
Study: NCT01082211

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 3D-Conformal External Beam
Description: Radiation was to be delivered in 2 fractions per day, each of 1.5 Gy, separated by at least six hours, given in 15 consecutive working days to a total of 30 fractions and 45 Gy. Radiation was to be prescribed to the treatment unit isocenter, positioned at the approximate center of the planning target volume.
Study: NCT01386138

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psycho-education
Description: Receive RBT education and peer-support in a group format.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental
Description: Receive RBT education and a pro-active counseling method
Study: NCT03158480

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DC-CIK immunotherapy
Description: Cytokine-induced killer (CIK) cells are co-cultured with HPV induced dendritic cells (DCs); HPV specific DC-CIK will be induced to condylomata acuminata patients

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: DC-CIK immunotherapy
Description: Cytokine-induced killer (CIK) cells are co-cultured with HPV induced dendritic cells (DCs); HPV specific DC-CIK will be induced to condylomata acuminata patients
Study: NCT04508049

Intervention type: DEVICE
Group type: OTHER
Intervention: qMT-MRI to detect fibrosis.
Description: The hypothesis underlying this proposal is that qMT would reliably detect development of renal fibrosis at both 1.5T and 3.0T in subjects with RVD. Patients will be studied with MRI (for fibrosis) and CT (for renal function).
Study: NCT01220388

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: L-lysine
Description: L-lysine, 4,95 G at day : 0,55 G 3 times a day, orally, during meals

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo, 3 times a day, orally, during meals
Study: NCT03835624

Intervention type: DIAGNOSTIC_TEST
Intervention: interleukin 33
Description: serum and synovial fluid samples will be obtained from patients and serum samples from controls to measure interleukin 33 and its relative mRNA expression in peripheral blood mononuclear cells by PCR

Intervention type: DIAGNOSTIC_TEST
Intervention: interleukin 33
Description: serum and synovial fluid samples will be obtained from patients and serum samples from controls to measure interleukin 33 and its relative mRNA expression in peripheral blood mononuclear cells by PCR
Study: NCT03268200

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: segmental reexamination
Description: segmental reexamination during colonoscopy
Study: NCT03822663

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Caffeine supplementation
Description: The experimental procedure for each athlete includes an acute CAF supplementation in a different-dose crossover regimen in order to assess whether the dose affects the actual physical capacity and discipline-specific exercise performance (doses: 3.0-, 6.0- and 9.0 mg/kg of body mass, respectively). CAF (pure pharmaceutical caffeine) will be administered in the dissolved form. On testing days, the supplements will be taken 70 min before physical and exercise capacity test session. Between the CAF and PLA or a PLA and CAF treatments, a minimum 7-day washout period will be introduced.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo treatment
Description: The experimental procedure for each athlete will include PLA supplementation. Placebo will be administered in the dissolved form. On testing days, the PLA will be taken 70 min before physical and exercise capacity test session. Between the PLA and CAF or a CAF and PLA treatments, a minimum 7-day washout period will be introduced.
Study: NCT01444859

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Trenev Trio®/Healthy Trinity®
Description: Trenev Trio®/Healthy Trinity® (1 capsule, 2x/day for 10 weeks), which offers a daily dose of: a) Lactobacillus acidophilus NAS strain (10 billion CFU), b) Bifidobacterium bifidum Malyoth strain (40 billion CFU), and c) Lactobacillus delbrueckii subspecies bulgaricus LB-51 strain (10 billion CFU)
Study: NCT01497925

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADI-PEG 20
Description: Dosage: 4.5, 9, 18 and 36 mg/m2. Frequency: weekly.
Study: NCT02404688

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Active delta-9-THC
Description: Low dose (0.015 mg/kg = 1.05 mg in a 70 kg individual) THC, dissolved in alcohol. This dose is roughly equivalent to smoking approximately 1/4 of a marijuana cigarette, or joint. Administered over 20 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Active delta-9-THC
Description: Low dose (0.015 mg/kg = 1.05 mg in a 70 kg individual) THC, dissolved in alcohol. This dose is roughly equivalent to smoking approximately 1/4 of a marijuana cigarette, or joint. Administered over 20 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Control: small amount of alcohol (quarter teaspoon), with no THC. Administered over 20 minutes.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Control: small amount of alcohol (quarter teaspoon), with no THC. Administered over 20 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Active Ethanol
Description: Target BrAC of 0.04% reached over 20 minutes and then clamped to maintain this dose for an additional 60 minutes. This dose is equivalent to consuming approximately 2 drinks over 1 hour. Administered over a total of 80 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Active Ethanol
Description: Target BrAC of 0.04% reached over 20 minutes and then clamped to maintain this dose for an additional 60 minutes. This dose is equivalent to consuming approximately 2 drinks over 1 hour. Administered over a total of 80 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Control: no alcohol, administered for a total of 80 minutes.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Control: no alcohol, administered for a total of 80 minutes.
Study: NCT01600365

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ophthalmic gel (placebo)
Description: Ophthalmic gel (placebo): applied in affected eye 4 times daily for 10 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ganciclovir
Description: Ophthalmic gel ganciclovir 0,3%: applied in affected eye 4 times daily for 10 days
Study: NCT01404156

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: (Epirubicin Cisplatin 5-Fluorouracil / Xeloda) OR 5-Fluorouracil Leucovorin Oxaliplatin Docetaxel
Description: NEOADJUVANT CHEMOTHERAPY (OPTION of CHEMO REGIMEN 1 or 2)~1) FLOT - Four x 14 day cycles FLOT preoperatively and 4 cycles postoperatively (within 4-10 weeks after surgery): 5-Fluorouracil 2600 mg/m², day 1 IV every 14 days Leucovorin 200 mg/m², day 1, IV., every 14 days Oxaliplatin 85 mg/m², day 1, IV, every 14 days Docetaxel 50mg/m2, day 1, IV, every 14 days~2) ECF / ECX - Three x 21-day cycles ECF preoperatively and 3 cycles postoperatively (within 4-10 weeks after surgery): Epirubicin (50 mg/m²,mg per square meter of body-surface area) by intravenous bolus on day 1 IV Cisplatin: 60 mg/m², mg per square meter intravenously with hydration on day 1 IV 5-Fluorouracil: 200 mg/m², mg per square meter daily for 21 days by continuous IV infusion 5-FU may be substituted with Capecitabine (Xeloda) 625mg/m2, PO BID (ECX)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Carboplatin paclitaxel plus concurrent radiotherapy
Description: 5 cycles carboplatin and paclitaxel given on days 1, 8, 15, 22 and 29 preoperatively:~* paclitaxel: 50 mg / m2 IV over 1 hour~* carboplatin: dosed to an area under the curve of 2, by Calvert formula, as a 1 hour IV infusion~Radiation Therapy Concurrent radiation therapy will begin within 24 hours of initiation of chemotherapy for patients randomized to chemoradiation treatment.~1. Dose specifications:~1. Phase 1: Total radiation prescription dose 45 Gy given in 25 fractions of 1.8 Gy per fraction, 5 fractions / week, one treatment / day, starting on the first day of first cycle of chemotherapy. This total radiation dose option is acceptable if boost dose is not possible due to clinical reasons or dosimetric constraints.~2. Phase 2: (GTV only) Boost is not mandatory and up to the discretion of radiation oncologist. Total radiation prescription dose 5.4 Gy given in 3 fractions of 1.8 Gy per fraction, 5 fractions / week, one treatment .
Study: NCT01404377

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: infiltration with ropivacaine solution
Description: Patients are allocated randomly into two arms on the morning of surgery, using random numbers and sealed envelopes. In the treated group infiltration is performed with a ropivacaine 7.5 mg.ml-1 solution and in the control group with an isotonic saline solution. In the two groups patients are operated under and nitrous oxide for maintenance. Dexamethasone 4 mg was given intravenously after anaesthetic induction for prevention of postoperative nausea and vomiting. Twenty milliliters of the allocated solution were used at the end of the surgical procedure to infiltrate the subcutaneous and deep layers at the level of the breast and axilla surgical incision.
Study: NCT01741636

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: educational intervention
Description: Undergo Survivorship Care Planning

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire administration
Description: Ancillary studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Description: Ancillary studies
Study: NCT00551187

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V504
Description: V504 0.5 ml injection in 3 dose regimen for 6 month treatment period.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Comparator: Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine
Description: Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine 0.5 ml injection in 3 dose regimen for 6 month treatment period.
Study: NCT02572076

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Motus Cleansing System
Study: NCT05982483

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Erector Spinae plane block using 20 ml of bupivicaine 0.25%
Description: Utilizing the in line approach, a 22 gauge 3.5 spinal needle was guided the the tip of the transverse process corresponding to the area of maximal tenderness or central to the reported area of spasm. 1% lidocaine with epinephrine was used for skin anaesthesia and for hydro-localization of the needle tip on approach to the tip of the transverse process. Once the needle tip made contact with the transverse process, 2-3 ml of 1% lidocaine with epinephrine was injected to open the ESP plane. If there was no reported tachycardia after approximately 45 seconds, 20 ml of 0.25% bupivicaine was injected into the ESP plane.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Analgesia as dictated by the treating emergency physician
Study: NCT00166543

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAS-108

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAS-108

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAS-108
Study: NCT02453334

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Injectafer

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Study: NCT01444859

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Daily placebo for 10 weeks
Study: NCT03403426

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Wingman Crossing Catheter
Description: Endovascular CTO crossing
Study: NCT01763580

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Oral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolone
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone
Description: Oral
Study: NCT00551187

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine
Description: Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine 0.5 ml injection in 3 dose regimen for 6 month treatment period.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: Placebo (unspecified)
Description: V504 Placebo in 3 dose regimen for 6 month treatment period.
Study: NCT03374917

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-951
Description: powder for solution